hVIVO plc (LON:HVO – Get Free Report) rose 10% during mid-day trading on Monday . The company traded as high as GBX 22 ($0.27) and last traded at GBX 21.25 ($0.26). Approximately 7,804,669 shares changed hands during trading, an increase of 164% from the average daily volume of 2,961,263 shares. The stock had previously closed at GBX 19.33 ($0.24).
hVIVO Price Performance
The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The firm has a market cap of £129.27 million, a PE ratio of 633.33 and a beta of 0.97. The business’s fifty day moving average is GBX 20.14 and its 200-day moving average is GBX 25.64.
hVIVO Company Profile
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Recommended Stories
- Five stocks we like better than hVIVO
- 10 Best Airline Stocks to Buy
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3 Steel Stocks Soaring After Tariff Announcements
- Insider Buying Explained: What Investors Need to Know
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
